Kidney Cancer

“The question of who is a candidate for active surveillance is hard to answer because this is a bedside, gut decision," says Primo Nery Lara, Jr, MD.

Gennady Bratslavsky, MD highlighted studies examining (neo)adjuvant immunotherapy in the setting of nephrectomy for locally advanced disease, such as the PROSPER (NCT03055013) and KEYNOTE-564 (NCT03142334) trials.

The approval is based on the pivotal phase 3 KEYNOTE-564 trial.

Naomi B. Haas, MD, discusses efforts to improve care in locally advanced renal cell carcinoma through research in the neoadjuvant setting.

Ziad Bakouny, MD, MSc, highlights efforts to gain an understanding of the biology and genomic drivers of the rare and aggressive form of kidney cancer.

On this episode of Cleveland Clinic’s Cancer Advances podcast, urologic surgeon Steven Campbell, MD, PhD, discusses the longstanding controversy between partial nephrectomy and radical nephrectomy for patients with localized kidney cancer.

The trial is exploring tivozanib combined with the investigational HIF2α-inhibitor NKT2152 in patients with renal cell carcinoma who have not responded to or have relapsed from prior treatments.

The phase 3 CONTACT-03 trial is specifically accruing patients with inoperable, locally advanced or metastatic renal cell carcinoma with disease progression after receiving an immune checkpoint inhibitor as the immediate prior therapy.

At a median follow-up of 10.4 months (IQR: 5.8-16.4), SAbR extended drug efficacy by more than 6 months in 70% of mRCC patients (14 out of 20; 95% CI: 49.9-90.1).

Eric Jonasch, MD, shares insight on the most pivotal developments in renal cell carcinoma over the past few years.

A retrospective analysis of the phase 3 CheckMate-214 trial showed a treatment-free survival advantage with the immunotherapy combination versus the targeted therapy sunitinib in patients with advanced renal cell carcinoma.

The new drug application is supported by a prior submission for premarket approval of Dovitinib-DRP, a companion diagnostic used to identify patients with RCC most likely to respond to dovitinib.

Adjuvant pembrolizumab was recommended for approval in renal cell carcinoma based on results from the phase 3 KEYNOTE-564 trial.

“The initial phase 1b data of batiraxcept in combination with cabozantinib are impressive and point toward the role of dual AXL and VEGF inhibition in the treatment of clear cell renal cell carcinoma,” said Eric Jonasch, MD.

The approval was based on data from the phase 3 KEYNOTE-564 trial.

Investigators reported that utilizing dosing interruptions or modifications for lenvatinib is an important part of managing toxicities.

"In this cohort study, cabozantinib showed considerable intracranial activity and an acceptable safety profile in patients with RCC and brain metastases," the authors wrote.

“These findings are exciting because we’re challenging the dogma in radiation oncology that RCC is biologically radioresistant," ,” said lead author Chad Tang, MD.

The study is specifically exploring the combination in patients with MET-driven kidney cancer.

Tian Zhang , MD, discusses the adaptive phase 3 PDIGREE study comparing immunotherapy only versus immunotherapy/TKI regimens in patients with advanced kidney cancer.

“Clearly, we are now in that era of TKIs in addition to checkpoint inhibitors, and so…it makes logical sense from the place we're at [in] the moment in renal cancer treatment with those combinations of treatment,” says Grant Stewart, MD.

“The concept behind the NAXIVA trial was to treat these patients with pre-surgical neoadjuvant targeted therapy with a means of downstaging that venous tumor thrombus, reducing the extent of it to try and make the surgery less morbid to the patient and to potentially improve survival,” says Grant Stewart, MD.

The combination demonstrated encouraging clinical activity in patients with both clear cell and non–clear cell renal cell carcinoma.